Abstract Body

Background: Tenofovir disoproxil fumarate (TDF) has been used in all major published clinical trials of HIV pre-exposure prophylaxis (PrEP), and is a component of the only drug (TDF/emtricitabine) currently approved for PrEP. However, little is known about the effect of TDF monotherapy on individuals seroconverting while receiving PrEP. We examined immune functions in Bangkok Tenofovir Study (BTS) participants randomized to placebo or TDF who seroconverted during the study.

Methods: All available post-infection blood specimens from all seroconverting participants were analyzed. We performed flow cytometry using standard antibody (Ab) panels to characterize differentiation and activation status of circulating CD4+ and CD8+ T cells, and intracellular cytokine staining (ICS) using overlapping HIV-1 peptides spanning Gag to characterize HIV-specific T lymphocyte responses. We measured HIV-1 NAb titers in blood against two tier-1 laboratory strains (SS1196.1 [subtype B] and Th023 [CRF01-AE]) using a luciferase reporter assay in TZM-bl cells. Treatment groups were compared using the Wilcoxon rank sum test.

Results: Forty-eight seroconverters (TDF = 14, placebo = 34) provided 128 specimens collected a median of 221 days (r 40-1159) post infection and 121 days (r 41-1159) after cessation of TDF use. In TDF recipients, CD8+ T cells had significantly lower expression of intermediate, transitional effector and central effector memory cell markers compared with placebo recipients (p < 0.02). TDF and placebo recipients did not differ in the distribution of CD4+ cells (p > 0.05). In TDF recipients, CD8+ and CD4+ T-cells had lower expression of activation markers (CCR5 +/- HLA-DR and CD38) and programmed cell death protein 1 (p < 0.02). There was no difference between groups in ICS responses, neutralizing Ab titers, plasma viral load (PVL), or CD4 count.

Conclusions: TDF PrEP was associated with a significant skewing of CD8+ differentiation from transitional and central memory states towards an effector phenotype, In addition, TDF recipients had reduced activation of CD4 and CD8 cells, and lower expression of one marker associated with programmed cell death on activated cells. However, we did not detect significant differences in functional cellular or humoral responses, absolute peripherally circulating CD8+ or CD4+ cell counts, or PVL between groups. These data indicate that TDF PrEP could have lasting effects on T cell differentiation and cellular exhaustion in individuals becoming HIV infected while on therapy.